Tanezumab Proves Effective in Treating Hip and Knee OA

In a recent study, researchers found tanezumab successfully helped with functionality and pain management in patients with osteoarthritis (OA) of the hip or knee. 

The randomized, double-blind, placebo-controlled, multicenter, parallel-group, 40-week study included 696 patients with hip or knee OA who had not responded to standard treatments. Patients eligible for inclusion had hip or knee OA based on clinical and radiographic ACR criteria; baseline Western Ontario and McMaster Universities (WOMAC) Pain and Physical Function scores of ≥ 5 (11-point scale); baseline Patient’s Global Assessment of OA (PGA-OA) of “fair,” “poor,” or “very poor”; and non-responsiveness/intolerance to acetaminophen, NSAIDs, and either tramadol or opioids (or were unwilling to take opioids). Patients either received placebo (n = 232) or tanezumab administered in two treatment regimens over 16 weeks: fixed-dosing (2.5 mg at baseline and week eight; n = 231) or step-up dosing (2.5 mg administered at baseline and 5 mg at week eight; n = 233). 

By week 16, compared with the placebo group, tanezumab patients in both dosing groups showed significant improvements in WOMAC Pain (mean change from baseline: placebo, -2.64; tanezumab 2.5 mg, -3.23; tanezumab 2.5 mg/5 mg, -3.37), WOMAC Physical Function (mean change from baseline: placebo, -2.56; tanezumab 2.5 mg, -3.22; tanezumab 2.5 mg/5 mg, -3.45), and PGA-OA (mean change from baseline: placebo, -0.65; tanezumab 2.5 mg, -0.87; tanezumab 2.5 mg/5 mg, -0.90). Adverse events occurred in 115 (49.6%) placebo patients, 128 (55.4%) fixed-dosing tanezumab patients, and 109 (46.8%) step-up dosing tanezumab patients. The most common adverse effects across all three groups were nasopharyngitis, pain in extremity, and paresthesia. Four patients in each group experienced serious adverse events. 

The study’s findings were presented at the annual meeting of the American College of Rheumatology. 

“Increasing the dose to 5 mg at Week 8 was associated with modest additional benefit versus continuation on tanezumab 2.5 mg,” the researchers wrote. “This study demonstrates that SC tanezumab may be an effective option for patients who have demonstrated intolerance or incomplete response to standard treatments for OA.” 

Losing Weight with Knee Osteoarthritis: More is Better 

Despite Increase in Osteoarthritis, Knee Arthroscopy on the Decline in Adults 

Knee Osteoarthritis Linked to Obesity 

FDA Guidance for Osteoarthritis 

Sources: American College of Rheumatology, MedPage Today